SVG103

Small molecule

SSovargen

SVG103 is one of 16 small molecule programs targeting Tuberous Sclerosis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tuberous SclerosisActive, not recruiting

Tuberous SclerosisPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Tuberous Sclerosis

#DrugCompanyPhaseTrials

Afinitor

Novartis

Approved

8 2

Epidiolex

Jazz Pharmaceuticals

Approved

1 3

Rapamune

PPrism Pharmaceuticals

Approved

2 4

Fintepla

IImmedica Pharma AB

Approved

—5

Rocaltrol

Alnylam Pharmaceuticals

Phase 3

1 6

Sabril

Lundbeck

Phase 3

1 7

GWP42003-P

Jazz Pharmaceuticals

Phase 3

2 8

RAD001

Novartis

Phase 3

2 9

Rapamycin

MMaastricht Radiation Oncology

Phase 3

4 10

Bayer Aspirin

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Not yet recruiting

Tuberous Sclerosis

NCT07287202

Clinical

Trials by Indication[1]

Tuberous Sclerosis1 trial

Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

Not yet recruiting·SSovargen·Phase 1/2·NCT07287202·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SVG103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SVG103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SVG103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sovargen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: SSovargen

SVG103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Tuberous Sclerosis1 trial

References

Drug Info

Quick Facts

Related News